Coya Therapeutics, Inc. (NASDAQ:COYA) Sees Large Decrease in Short Interest

Coya Therapeutics, Inc. (NASDAQ:COYA) saw a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 160,700 shares, a decline of 9.1% from the July 31st total of 176,700 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 55,900 shares, the days-to-cover ratio is currently 2.9 days.

Analyst Upgrades and Downgrades

COYA has been the topic of a number of research reports. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Wednesday, June 5th. Rodman & Renshaw initiated coverage on shares of Coya Therapeutics in a report on Thursday, June 13th. They issued a “buy” rating and a $18.00 price target on the stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new position in shares of Coya Therapeutics during the 2nd quarter valued at $101,000. Gilbert & Cook Inc. purchased a new position in shares of Coya Therapeutics during the 2nd quarter valued at $61,000. Vanguard Group Inc. grew its position in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after purchasing an additional 750,338 shares in the last quarter. Greenlight Capital Inc. grew its position in shares of Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock valued at $9,441,000 after purchasing an additional 805,959 shares in the last quarter. Finally, AIGH Capital Management LLC grew its position in Coya Therapeutics by 92.6% in the fourth quarter. AIGH Capital Management LLC now owns 1,031,977 shares of the company’s stock worth $7,381,000 after acquiring an additional 496,183 shares in the last quarter. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics Stock Performance

Coya Therapeutics stock traded up $0.09 during mid-day trading on Tuesday, reaching $6.12. The company’s stock had a trading volume of 28,734 shares, compared to its average volume of 67,641. Coya Therapeutics has a 12-month low of $3.21 and a 12-month high of $10.69. The company has a market capitalization of $89.46 million, a P/E ratio of -7.32 and a beta of 0.59. The firm’s fifty day moving average price is $6.36 and its two-hundred day moving average price is $7.77.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.